Sugi Predict

Sugi Predict / Compounds / SCHEMBL1749228

SCHEMBL1749228

SCHEMBL1749228

Cc1ccc(S(=O)(=O)n2ccc3c(Cl)ccnc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ PKM P14618 3/20 0.49
▸ BRD4 O60885 1/20 0.43
▸ ENPP3 O14638 2/20 0.43
▸ ENPP1 P22413 2/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HSD11B1 P28845 1/20 0.42
▸ HTT P42858 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ POLB P06746 2/20 0.42
▸ ALDH3A1 P30838 1/20 0.42
▸ NOD1 Q9Y239 1/20 0.42
▸ RAPGEF4 Q8WZA2 2/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ COMT P21964 1/20 0.38
▸ HTR6 P50406 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29634511 1.00 L3MBTL1 (0.59) L3MBTL1PKMBRD4ENPP3ENPP1
SCHEMBL25420078 0.86 PKM (0.49) L3MBTL1PKMENPP3ENPP1CYP2C19
SCHEMBL29959107 0.86 CYP2C19 (0.58) L3MBTL1PKMENPP3ENPP1CYP2C19
SCHEMBL414843 0.86 CYP2C19 (0.58) L3MBTL1PKMENPP3ENPP1CYP2C19
SCHEMBL2237896 0.86 L3MBTL1 (0.62) L3MBTL1PKMBRD4CYP2C19HTT
SCHEMBL1749202 0.86 L3MBTL1 (0.62) L3MBTL1PKMBRD4CYP2C19HSD11B1
SCHEMBL1354366 0.83 L3MBTL1 (0.59) L3MBTL1PKMBRD4CYP2C19HTT
SCHEMBL30081932 0.83 L3MBTL1 (0.59) L3MBTL1PKMBRD4CYP2C19HTT
SCHEMBL28735134 0.83 L3MBTL1 (0.59) L3MBTL1PKMBRD4CYP2C19HTT
SCHEMBL28927986 0.83 L3MBTL1 (0.59) L3MBTL1PKMBRD4CYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111499676-A 4-chloro-3-nitro-1-p-toluenesulfonyl-7-azaindole derivative and preparation method and application thereof 绍兴文理学院 2020-08-07 — — CN claimed
EP-4688778-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Biogen MA Inc. (US) 2026-02-11 — — EP disclosed
US-20250387400-A1 TYK2 INHIBITORS BIOGEN MA INC (US) 2025-12-25 — — US disclosed
US-12478620-B2 Cyano-substituted cyclic hydrazine derivative and application thereof E-NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD (CN) 2025-11-25 — — US disclosed
EP-4547674-A1 TYK2 INHIBITORS Biogen MA Inc. (US) 2025-05-07 — — EP disclosed
US-20240360157-A1 TYK2 INHIBITORS BIOGEN MA INC. 2024-10-31 — — US disclosed
WO-2024211696-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES BIOGEN MA INC. (US) 2024-10-10 — — WO disclosed
US-12024516-B2 Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-02 — — US disclosed
WO-2024006493-A1 TYK2 INHIBITORS BIOGEN MA INC. (US) 2024-01-04 — — WO disclosed
US-11858933-B2 Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-01-02 — — US disclosed
US-6897207-B2 Azaindoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US disclosed
US-20040198737-A1 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-10-07 — — US disclosed
US-6770643-B2 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-08-03 — — US disclosed
US-20040053931-A1 Azaindoles AVENTIS PHARMACEUTICALS INC. 2004-03-18 — — US disclosed
EP-1397360-A1 AZAINDOLES Aventis Pharma Limited (GB) 2004-03-17 — — EP disclosed
US-20040009983-A1 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-01-15 — — US disclosed
WO-2003000688-A1 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2003-01-03 — — WO disclosed
WO-2003000690-A1 SYNTHESIS OF HETEROCYCLIC COMPOUNDS EMPLOYING MICROWAVE TECHNOLOGY AVENTIS PHARMACEUTICALS INC. (US) 2003-01-03 — — WO disclosed
EP-1263759-A2 AZAINDOLES Aventis Pharma Limited (GB) 2002-12-11 — — EP disclosed
WO-2001047922-A2 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2001-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198737-A1 Azaindoles CCNY, CCNO, CNKSR1 L3MBTL1 2911/4885PKM 2958/4885BRD4 566/4885
US-20040053931-A1 Azaindoles CDKN1A, CDK7, CDK2 L3MBTL1 4557/4885PKM 518/4885BRD4 1593/4885
US-20040009983-A1 Azaindoles CCNY, CCNO, CKS2 L3MBTL1 2911/4885PKM 3503/4885BRD4 723/4885
US-20250387400-A1 TYK2 INHIBITORS TYK2, CSNK2A3, CSNK2A1 L3MBTL1 2095/4885PKM 3210/4885BRD4 335/4885
US-12478620-B2 Cyano-substituted cyclic hydrazine derivative and application thereof WNK1, STK35, CDK1 L3MBTL1 3691/4885PKM 335/4885BRD4 2294/4885
US-11858933-B2 Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof JAK1, JAK2, JAK3 L3MBTL1 2430/4885PKM 516/4885BRD4 314/4885
US-12024516-B2 Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof JAK1, JAK2, JAK3 L3MBTL1 2430/4885PKM 516/4885BRD4 314/4885
US-20240360157-A1 TYK2 INHIBITORS TYK2, JAK2, ABL1 L3MBTL1 2688/4885PKM 772/4885BRD4 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.